Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that GlaxoSmithKline's NS-2359 will be the first triple reuptake inhibitor to market, launching in 2009 and growing steadily in the following five years. Merck's triple reuptake inhibitor, DOV-216303, will enter the market in 2011. Both compounds will reach approximately $4 billion in sales in 2014.

According to the new Pharmacor study entitled The Antidepressant Market Through 2014: Focus on Emerging Therapies and New Indications, cost-saving policies set by third-party payers will constrain the antidepressant market, especially for emerging agents with little to differentiate themselves.

"Only antidepressants with novel mechanisms of action, and presumably those labeled for treatment of a novel indication, will be able to compete within the growing selection of antidepressants," said Anathea Waitekus, analyst at Decision Resources, Inc. "These drugs will have the greatest chance of earning favorable pricing and reimbursement status, as well as formulary inclusion."

About The New Study

The new study, The Antidepressant Market Through 2014: Focus on Emerging Therapies and New Indications, explores the following topics:

  * Which emerging antidepressants will achieve blockbuster status?   * What strategies are developers using to create blockbuster     antidepressant agents through 2014, despite generic competition,     regulatory constraints, and market crowding?   * What regulatory and reimbursement hurdles will emerging agents face in     the G7? What drives a drug's favorable reimbursement status in various     markets? Which compounds are more likely to secure favorable status?     Which might be at risk?   * In which indications will emerging agents garner their sales? Which of     the non-psychiatric markets represents an ideal opportunity for     antidepressants? What are the opportunities and hurdles for     antidepressants in non-psychiatric indications?   * How will emerging antidepressant drugs compete?   * What is the value of the market historically, currently, and in 10     years?   * What are the sales trajectories, by year, of leading compounds between     2000 and 2014? Which events have influenced these trajectories? How     will future events impact sales trends of these molecules?    About Pharmacor from Decision Resources 

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

Celgene's Revlimid Will Generate $321 Million in Sales for the Multiple Myeloma Drug Market in 2009

View Now